Articles
SAHPRA clarifies the benefits and risks of medroxyprogesterone acetate
SAHPRA Issues Warning: Medroxyprogesterone Acetate (MPA) Products to Include Meningioma Risk—What You Need to Know!
The South African Health Products Regulatory Authority (SAHPRA) has recommended that the product information of medroxyprogesterone acetate (MPA)-containing products be amended by updating the safety warnings to include the potential risk of meningioma.
MPA is a synthetic oral and injectable form of the hormone progesterone and is used for contraception and the management of endometriosis-associated pain. It is also indicated in the palliative treatment of recurrent and/or metastatic endometrial cancer, renal cancer and breast cancer in postmenopausal women.
Click here to access the article.